Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, is expanding its Maryland campus to accommodate the company’s rapid growth as it works to develop its candidate vaccine against COVID-19 and advance its influenza vaccine for global markets. Novavax has secured two additional properties in Gaithersburg, MD, to support the company’s immediate need for additional laboratory and office space for manufacturing, R&D and business operat...